RCEL vs SYK

For growth investors, AVITA Medical, Inc.

(RCEL) is the stronger pick with 11. 5% revenue growth year-over-year, versus 11. 2% for Stryker Corporation (SYK). Stryker Corporation (SYK) offers the better valuation at 34. 8x trailing P/E (19. 5x forward), making it the more compelling value choice. Analysts rate AVITA Medical, Inc. (RCEL) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

1%, compared to -77. 2% for AVITA Medical, Inc. (RCEL). Over 10 years, the gap is even starker: SYK returned +185. 6% versus RCEL's -57. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

55β versus AVITA Medical, Inc. 's 1. 83β — meaning RCEL is approximately 234% more volatile than SYK relative to the S&P 500.

By revenue growth (latest reported year), AVITA Medical, Inc.

(RCEL) is pulling ahead at 11. 5% versus 11. 2% for Stryker Corporation (SYK). On earnings-per-share growth, the picture is similar: AVITA Medical, Inc. grew EPS 27. 2% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, RCEL leads at 27. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Stryker Corporation (SYK) is the more profitable company, earning 12.

9% net margin versus -67. 8% for AVITA Medical, Inc. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCEL leads at 89. 0% versus 19. 5% for SYK. At the gross margin level — before operating expenses — RCEL leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RCEL: 52.

7% to $6. 75.

In this comparison, SYK (1.

1% yield) pays a dividend. RCEL does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +185. 6% 10Y return). AVITA Medical, Inc. (RCEL) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +185. 6%, RCEL: -57. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

SYK pays a dividend while RCEL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.